PERCEPTIVE ADVISORS LLC

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$5.34B2026 Q3+ $399.9M options (notional, not included)
Positions108
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.49.7%

PERCEPTIVE ADVISORS LLC reported 108 positions worth $5.34B as of September 30, 2026 (13F filed November 16, 2026). Largest holding: PRAX (10.3%). Biggest move: new buy FRNM ($198.5M).

10 / 108 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 PRAXPraxis Precision Medicines$589.7M10.27%2,024,781——+6.5%
▸ 2 AMLXAmylyx Pharmaceuticals$307.7M5.36%10,573,735——-4.5%
▸ 3 SYRESpyre Therapeutics$292.1M5.09%3,280,943——+16.8%
▸ 4 MRNAPutModerna$269.6M notional4.70%1,400,000———
▸ 5 CELCCelcuity$252.9M4.40%3,179,794——-23.8%
▸ 6 RYTMRhythm Pharmaceuticals$241.1M4.20%2,532,556——+12.9%
▸ 7 ROIVRoivant Sciences$238.1M4.15%6,510,961——+5.6%
▸ 8 RLAYRelay Therapeutics$229.8M4.00%12,730,336——-4.3%
▸ 9 ASNDAscendis Pharma A/S$221.3M3.86%971,521——+20.9%
▸ 10 TVTXTravere Therapeutics$208.6M3.63%3,542,913——-15.6%

Pro Feature

The remaining 98 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does PERCEPTIVE ADVISORS LLC hold as of Q3 2026?

PERCEPTIVE ADVISORS LLC reported 108 positions worth $5.34B in its Q3 2026 13F filing. Largest positions: PRAX (10.3%), AMLX (5.4%), SYRE (5.1%), MRNA (4.7%) and CELC (4.4%).

What did PERCEPTIVE ADVISORS LLC buy in Q3 2026?

New positions: FRNM, WAT, IRD, SLS and LKFT (26 in all). Added to: MRNA, AMLX, NRIX, SLS and AORT (15 in all).

What did PERCEPTIVE ADVISORS LLC sell in Q3 2026?

Reduced: SYRE, ROIV, BIIB, ASND and UNH (42 in all). Sold out entirely: NUVLEUR, APOGEE THERAPEUTICS INC, IONS, JAZZ and SION (27 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.